12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TriRima: Phase II started

CeNeRx began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 125 mg TriRima twice daily in 360 patients. CeNeRx has rights to TriRima from Krenitsky under a 2005...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >